SoftOx Solutions AS (Oslo) is a medical technology company. With its patented technology, SoftOx will develop a portfolio of antimicrobial products to aid the global health challenges of both AMR and chronic skin infections. The company develops its products in collaboration with leading research institutions in the Nordic region. The work is supported by the Research Council of Norway and the EU. The first product will be introduced to the European market in 2020.
SoftOx has raised a total of NOK 190 million, of which NOK 50 million was raised before the IPO (Initial Public Offering) at an average price of NOK 13 per share. After the IPO, SoftOx have had the following placements:
- 21/12/2018 - NOK 15 million Private Placement with support from new and existing shareholders. Private Placement consists of 680 000 new shares, each at a subscription price of NOK 22.
- 12/12/2019 - SoftOx has completed Private Placement, raising gross proceeds of approximately NOK 75 million through issuance of 3,125,000 new shares (the "New Shares") at a price of NOK 24 per share. Private Placement received support from both new and existing shareholders.
- 16/12/2020 SoftOx has completed a Private Placement, raising gross proceed of approximately NOK 50 million through issuance of 909,090 new shares, at a price per Offer Share of NOK 55. The Private Placement consists of two separate tranches: one tranche with